Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Forge Life Science Partners is a Massachusetts-based venture capital firm founded in 2022, focusing exclusively on the life sciences sector. The firm is backed by B-FLEXION, the Bertarelli family's multi-strategy investment platform, which manages billions across various investment strategies. This affiliation provides Forge with significant institutional support, enhancing its ability to invest in groundbreaking healthcare solutions.
The firm operates with a team of experienced biotech investors, operators, and entrepreneurs, all of whom bring decades of expertise in drug discovery and development. Forge Life Science Partners has quickly established itself as a credible player in the life sciences investment space, with a portfolio that includes six companies and notable exits.
Forge Life Science Partners invests primarily in the biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health sectors. The firm emphasizes innovative therapeutics and technologies, targeting companies at various stages of development, from early-stage to growth-stage. This broad focus allows them to engage with a diverse range of startups that are developing solutions to pressing healthcare challenges.
Investment checks typically occur in Series A rounds, particularly for US-based startups. The firm seeks to partner with companies that demonstrate potential for significant impact in the healthcare sector, aligning with its mission to support the advancement of innovative healthcare solutions.
Forge Life Science Partners has made a total of six investments, primarily in Series A rounds. Notable portfolio companies include:
The firm has achieved two successful exits via acquisition, including Escient Pharmaceuticals and IDRx, showcasing its ability to identify and support high-potential companies in the life sciences sector.
Ben Auspitz - Founder, Managing Partner. Ben has extensive experience in the biotech sector, having led numerous investments and strategic initiatives in life sciences. His background includes significant roles in various investment firms, where he has focused on drug discovery and development.
Anand Mehra - Team member. Anand brings valuable expertise in the life sciences sector, contributing to the firm's investment strategy and portfolio management.
In July 2025, Forge Life Science Partners made a notable investment in SAB Biotherapeutics through a PIPE-II round. This investment reflects the firm's ongoing commitment to supporting innovative companies in the life sciences sector.
Additionally, Forge Life Science Partners successfully led a $120M Series C round for Escient Pharmaceuticals, marking a significant milestone in their investment activity. The firm has also achieved two successful exits via acquisition, including Escient Pharmaceuticals and IDRx, demonstrating its ability to identify and support high-potential companies.
What are Forge Life Science Partners' investment criteria?
Forge Life Science Partners focuses on innovative therapeutics and technologies within the life sciences sector. They target companies at various stages of development, primarily in biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health.
How can I apply or pitch to Forge Life Science Partners?
While specific application details are not provided, founders are encouraged to reach out through professional networks or industry connections to initiate discussions. A well-prepared pitch deck highlighting the company's innovative approach and market potential is advisable.
What makes Forge Life Science Partners different from other VCs?
Forge Life Science Partners benefits from significant institutional backing from B-FLEXION, which allows them to provide not only capital but also strategic guidance and connections in the healthcare sector. Their team comprises experienced biotech investors and operators, enhancing their ability to support portfolio companies effectively.
What is the geographic scope of Forge Life Science Partners' investments?
The firm primarily invests in US-based startups, focusing on companies that are developing solutions within the life sciences sector.
What is the typical check size for investments?
While specific check sizes are not disclosed, Forge Life Science Partners primarily participates in Series A rounds, which typically range from several million to tens of millions of dollars, depending on the company's stage and needs.
What kind of post-investment involvement can portfolio companies expect?
Forge Life Science Partners provides significant value through its experienced team and extensive network in the biotech industry. They offer strategic guidance and connections to help portfolio companies navigate challenges and scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.